BRIM Biotechnology receives FDA orphan drug designation for treatment of neurotrophic keratitis
December 8th 2022Receiving FDA orphan drug designation allows the company to proceed with plans to advance the development of BRM424, a novel, first-in-class, potential treatment for neurotrophic keratitis.
Read More
OC-01 0.03 mg nasal spray is effective against dry eye disease regardless of menopausal status
November 29th 2022According to investigators, the risk for the development of dry eye disease is greater in postmenopausal women compared with those who have not reached menopause as a result of hormonal dysregulation of the ocular secretory glands.
Read More
Systemic factors may not be predictive of VA outcomes for diabetic patients after cataract surgery
October 26th 2022A team of investigators evaluated VA outcomes after cataract surgery and the factors associated with good visual outcomes in a population of patients diagnosed with type 2 diabetes.
Read More
Genentech recalling ranibizumab injection ocular implant in US
October 17th 2022The company noted that testing of a commercial supply of the implants, which included exposing them to multiple punctures with a needle, found they did not meet their standards. The company has notified the FDA, and is working with the agency on the recall process.
Read More